TCT-642 The Comparative Effectiveness and Safety of Cangrelor vs. In- lab Glycoprotein IIb/IIIa Inhibitor (GPI) in Patients Undergoing Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2)

Cangrelor is a recently approved intravenous P2 Y12 inhibitor for use in patients undergoing PCI. Glycoprotein IIb/IIIa inhibitors (GPI) are the more commonly used parenteral anti-platelet agent and are increasingly being used in an in-lab only fashion. The comparative efficacy of the two approaches